Article
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
Annals of oncology : official journal of the European Society for Medical Oncology - 1 Mar 2014
Schadendorf D, Amonkar M M, Milhem M, Grotzinger K, Demidov L V, Rutkowski P, Garbe C, Dummer R, Hassel J C, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu F S, Patel K, Casey M, Robert C
Abstract excerpt
BACKGROUND: In a randomized phase III study, trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600 mutation-positive melanoma. PATIENTS AND METHODS: Patients' quality of life (QOL) was assessed at baseline and follow-up visits using the European Organisation for Research and Treatment of Cancer Core QOL questionnaire. RESULTS: In the primary...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.